Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Brentuximab Vedotin

Review the clinical trials studying brentuximab vedotin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-18 of 18

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 342 locations
Brentuximab Vedotin in Combination with Pembrolizumab for the Treatment of Patients with CD30 Positive T-cell Non-Hodgkin Lymphoma
Status: Active
Location: 14 locations
Reduced Brentuximab Vedotin Doses in Treating Patients with Stage IB-IV Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis
Status: Active
Location: 8 locations
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Status: Active
Location: 7 locations
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Status: Active
Location: 7 locations
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with CD30-Positive Peripheral T-cell Lymphoma
Status: Active
Location: 5 locations
Brentuximab Vedotin in Early-Stage Hodgkin Lymphoma, RADAR Trial
Status: Active
Location: 5 locations
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Status: Active
Location: 3 locations
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Status: Active
Location: 3 locations
Fitness-Adapted, Pembrolizumab-Based Therapy for the Treatment of Untreated Classical Hodgkin Lymphoma in Patients 60 Years of Age and Above
Status: Active
Location: 3 locations
Brentuximab Vedotin in Treating Patients with CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ultra-low-dose Total-skin Electron Beam Radiation Therapy with Brentuximab vedotin for the Treatment of Stage I-IV Mycosis Fungoides
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone for the Treatment of Stage IIB-IV Hodgkin Lymphoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
PACIFIC: Primary Mediastinal large B-cell lymphoma treated with Antibody therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Brentuximab Vedotin in Combination with Mogamulizumab in Treating Patients with Stage II-IV Sezary Syndrome or Mycosis Fungoides
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
Status: Active
Location: 2 locations